-
Mashup Score: 5Source: link.springer.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9Preclinical safety and biodistribution of CRISPR targeting SIV in non-human primates - 7 month(s) ago
Gene Therapy – Preclinical safety and biodistribution of CRISPR targeting SIV in non-human primates
Source: www.nature.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Initiating targeted therapy for eligible patients with advanced non–small cell lung cancer (NSCLC) was found to improve outcomes, even when patients were started on nontargeted therapy but switched in a timely manner.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0Source: link.springer.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
The paucity of medications with novel mechanisms for pain treatment combined with the severe adverse effects of opioid analgesics has led to an imperative pursuit of non-opioid analgesia and a […]
Categories: Latest Headlines, RheumatologyTweet-
A new Editor’s Pick article highlighted in #PRF’s #PapersoftheWeek shares about a neural and molecular investigation into the paraventricular thalamic-nucleus accumbens circuit for pain sensation and #non-opioid #analgesia. https://t.co/bl22zZ1tTw https://t.co/lRbREDcyeg
-
A new Editor’s Pick article highlighted in #PRF’s #PapersoftheWeek shares about a neural and molecular investigation into the paraventricular thalamic-nucleus accumbens circuit for pain sensation and #non-opioid #analgesia. https://t.co/gEa7NBGJ8E https://t.co/1kj7LSU6Ed
-
-
Mashup Score: 32Cure of Disseminated Human Lymphoma with [177Lu]Lu-Ofatumumab in a Preclinical Model - 12 month(s) ago
Although immunotherapies that target CD20 on most non-Hodgkin lymphoma (NHL) cells have improved patient outcomes, current therapies are inadequate because many cases are, or become, refractory or undergo relapse. Here, we labelled the third-generation human anti-CD20 antibody ofatumumab with 177Lu, determined the in vitro characteristics of [177Lu]Lu-ofatumumab, estimated human dosimetry, and…
Source: Journal of Nuclear MedicineCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Source: link.springer.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Circ_0006220 promoted the malignant behaviors of NSCLC cells through mediating the miR-342-3p/GOT2 regulation cascade.
Source: PubMedCategories: Cardiac Surgery, Latest HeadlinesTweet
-
Mashup Score: 0Outcomes of penicillin allergy de-labeling by non-allergy specialists at an academic medical center. - 1 year(s) ago
Article InfoPublication HistoryAccepted: October 10, 2022Received: August 5, 2022Publication stageIn Press Journal Pre-ProofFootnotesConflict of interest statement: There are no conflicts of interest to report for both authors.Clinical Implication:Literature on safety and feasibility of penicillin allergy de-labeling by non-allergists is limited. We…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0
We identified underutilization of outpatient palliative care services within stage IV NSCLC patients. Many patients with NSCLC experience hospitalization the last month of life and in-hospital death.
Source: PubMedCategories: Latest Headlines, PulmonologyTweet
NOVEMBER ISSUE: Prognostic Factors for Survival of Stage IB #Non-smallCellLungCancer Patients: A 10-Year Follow-Up Retrospective Study.https://t.co/NZlPCS4zrQ https://t.co/cLkG9edzwe